Testimonial from NaDeNo Nanoscience AS, recipient of the Open Call
What is it like to work with the PHOENIX SEP?
NaDeNo Nanoscience AS, an innovative Norwegian spin-off from SINTEF, was selected to receive pro bono services in nanopharmaceutical development via the PHOENIX Single Entry Point from service providers within our second Open Call. NaDeNo Nanoscience has developed a proprietary platform technology to overcome drug delivery hurdles of hydrophobic drugs.
Their lead oncology candidate, PACAB-002, is a proprietary nanoformulation of cabazitaxel encapsulated in polymeric nanoparticles with currently ongoing preclinical studies showing even distribution and long drug retention in the treated area, tumor-specific accumulation, and over 97% tumor reduction compared to the free drug.
The PHOENIX-OITB services, accessed through the PHOENIX Single Entry Point (SEP) with its dedicated project and innovation managers, is helping NaDeNo Nanoscience AS to “greatly speed up the costly and lengthy process of taking our much-needed nanomedicine product to patients in urgent need of a better treatment solution”.
Andreas Åslund, scientific advisor and responsible for NaDeNo’s nanoformulation development and synthesis at SINTEF, which is NaDeNo’s R&D arm, spoke about his experience as a customer of PHOENIX-OITB / PHOENIX SEP.
